依诺替库单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | DLL4 |
| 临床资料 | |
| 其他名称 | 依诺苏单抗、REGN421 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1192578-27-0 |
| ChemSpider |
|
| UNII | |
| KEGG | |
依诺替库单抗（INN：Enoticumab；开发代号：REGN421），或译依诺苏单抗，是一种全人IgG1单克隆抗体，可结合人DLL4并破坏Notch介导的信号传导。该药物充当免疫调节剂。[1][2][3][4][5]
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-20]. （原始内容存档 (PDF)于2016-03-04）.
- ^ Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol. Cancer Ther. June 2016, 15 (6): 1344–52. PMC 4893925
. PMID 27009216. doi:10.1158/1535-7163.MCT-15-0144.
- ^ Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Res. October 2015, 75 (19): 4086–96. PMID 26377940. doi:10.1158/0008-5472.CAN-14-3773 .
- ^ Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin. Cancer Res. June 2015, 21 (12): 2695–703. PMID 25724527. doi:10.1158/1078-0432.CCR-14-2797 .
- ^ Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLOS ONE. 2014, 9 (11): e112371. Bibcode:2014PLoSO...9k2371M. PMC 4231048 . PMID 25393540. doi:10.1371/journal.pone.0112371 .
